855 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
AstraZeneca's (AZN) Q1 Earnings Beat, New Drugs Drive Sales http://www.zacks.com/stock/news/404479/astrazenecas-azn-q1-earnings-beat-new-drugs-drive-sales?cid=CS-ZC-FT-404479 Apr 26, 2019 - AstraZeneca (AZN) beats earnings and sales estimates in the first quarter. New drugs, especially cancer drugs, drive revenues.
Kidney-Cancer Market: Good for Patients, Hard for Investors https://www.fool.com/investing/2019/04/23/kidney-cancer-market-good-for-patients-hard-for-in.aspx?source=iedfolrf0000001 Apr 23, 2019 - Drugmakers battle for patients.
What's in the Cards for AstraZeneca (AZN) in Q1 Earnings? http://www.zacks.com/stock/news/392203/whats-in-the-cards-for-astrazeneca-azn-in-q1-earnings?cid=CS-ZC-FT-392203 Apr 23, 2019 - AstraZeneca (AZN) will report first-quarter results on Apr 26. New drugs likely to drive sales.
Here Are the Key Takeaways From J&J's Q1 Earnings Report http://www.zacks.com/stock/news/386860/here-are-the-key-takeaways-from-jjs-q1-earnings-report?cid=CS-ZC-FT-386860 Apr 18, 2019 - Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.
Top Analyst Reports for Wells Fargo, UnitedHealth & Merck http://www.zacks.com/research-daily/382658/top-analyst-reports-for-wells-fargo-unitedhealth-merck?cid=CS-ZC-FT-382658 Apr 17, 2019 - Top Analyst Reports for Wells Fargo, UnitedHealth & Merck
J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View http://www.zacks.com/stock/news/382057/jj-jnj-beats-on-q1-earnings-ups-2019-sales-growth-view?cid=CS-ZC-FT-382057 Apr 16, 2019 - J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019 and raises 2019 guidance for operational sales and adjusted operational EPS growth. Shares up in pre-market trading.
Why Merck (MRK) is a Top Dividend Stock for Your Portfolio http://www.zacks.com/stock/news/381325/why-merck-mrk-is-a-top-dividend-stock-for-your-portfolio?cid=CS-ZC-FT-381325 Apr 16, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Bristol-Myers' Shareholders Vote for Celgene Acquisition http://www.zacks.com/stock/news/381001/bristol-myers-shareholders-vote-for-celgene-acquisition?cid=CS-ZC-FT-381001 Apr 15, 2019 - Bristol-Myers' (BMY) gets a green signal from a majority of its shareholders for the merger with Celgene Corporation.
J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer http://www.zacks.com/stock/news/380671/jjs-erdafitinib-gets-fda-approval-for-urothelial-cancer?cid=CS-ZC-FT-380671 Apr 15, 2019 - FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group http://www.zacks.com/stock/news/379812/mercks-keytruda-gets-fda-nod-for-expanded-lung-cancer-group?cid=CS-ZC-FT-379812 Apr 12, 2019 - Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.

Pages: 1234567891011...86

<<<Page 6>